Senator Bernie Sanders is demanding what he calls the "death penalty" for a major American industry, igniting controversy over the risks this move could pose to U.S. competitiveness in the face of foreign adversaries.
The Vermont independent’s push, as described in Fox News reporting, targets the U.S. pharmaceutical sector. Sanders wants to strip certain drug manufacturers of their patent protections, a step he openly refers to as a "death penalty" for the companies involved. Critics warn that such a policy could cripple domestic drug development and open the door for China and other rivals to seize the advantage.
Sanders chairs the Senate Health, Education, Labor, and Pensions Committee. He has publicly attacked the pharmaceutical industry for what he calls "outrageous" pricing and profits, focusing especially on companies that manufacture insulin and other critical medications. He argues that removing patent rights from drug makers that charge “excessive” prices will help Americans afford their prescriptions.
During Senate hearings, Sanders said, “If a company is going to be so greedy as to charge the American people outrageous prices, maybe they should lose their patent rights.” He has characterized this proposed loss of exclusive rights as a “death penalty” for the offending companies, since it would allow competitors and even foreign firms to make generic versions of their drugs.
Critics, including several Republican lawmakers and industry leaders, warn that Sanders’ proposal goes far beyond targeting “greed.” They argue that removing patent protections could devastate innovation and investment in the U.S. pharmaceutical sector, an industry that remains one of the country’s leading sources of high-tech research and well-paying jobs.
Some Republican senators have voiced concerns that Sanders’ plan would not only punish American companies but also strengthen foreign adversaries. With U.S. firms stripped of their intellectual property, competitors in countries like China could quickly flood the market with cheap alternatives, potentially undercutting domestic producers and weakening America’s position in a critical field.
One unnamed industry executive warned, “If you take away our patent protections, you’re handing the keys to China. They’ll be able to copy our innovations and outcompete us overnight.”
Sanders’ proposal would require significant changes to federal law, as current patent protections are grounded in longstanding U.S. statutes designed to reward innovation and protect inventors’ rights. Lawmakers would need to revise key provisions to allow the government to revoke patents based on subjective assessments of pricing policies.
Republican members of the committee have raised legal concerns, questioning whether Congress has the constitutional authority to strip property rights from companies without due process. They also cited the risk that such a precedent could undermine the broader U.S. patent system, discouraging investment across multiple industries.
At a recent hearing, Sanders doubled down on his position:
“If a company is going to be so greedy as to charge the American people outrageous prices, maybe they should lose their patent rights.”
His opponents countered that the real-world consequences would reach far beyond a handful of “greedy” firms, impacting the country’s ability to lead in science and technology.
Authorities have not publicly confirmed how Sanders’ proposal would be implemented in practice, or how U.S. agencies would determine which companies lose their patent protections. Investigators and lawmakers will need to determine the economic impact of revoking patents and whether this move would comply with existing constitutional protections for private property.
No public results have been released about the potential for retaliation from foreign governments or the effect on U.S. jobs and drug availability. Critics are demanding more transparency and a full economic analysis before any legislative action proceeds.
The Senate committee is expected to continue debate on Sanders’ plan in the coming weeks. Republican lawmakers are pressing for hearings that bring in national security experts and industry representatives to spell out the risks to America’s global standing. Legal analysts say any bill that attempts to revoke patents based on pricing could face immediate court challenges from affected companies.
The stakes for American innovation and public safety could not be higher. Lawmakers from both parties face mounting pressure to balance affordable drug prices with the need to defend U.S. industry from foreign predation and legal overreach.
The push for a “death penalty” on U.S. patents poses a stark test of whether Congress can defend American innovation while keeping life-saving drugs within reach for families who need them.
